Over 20,000 transplants have been performed in the last 10 years in Canada, and the demand today is higher than ever. Complicating the problem, many transplanted organs are rejected, and there are still major issues with immunosuppression drugs. iGeneTRAiN has brought together the major transplant genetic studies, and now encompasses over 30,000 samples from over a dozen countries with approximately 800,000 genetic variants scanned across the genomes of these individuals. iGeneTRAiN is currently combining genetic data from these subjects with the aim of detecting genes and specific variants underpinning rejection, and other complications after rejection. A number of the iGeneTRAiN studies are also working on markers from urine and blood to predict rejection weeks to months before it manifests clinically. need your help to develop and expand programs such as this.

Canadian Committee Members

Matthew B. Lankree, MD, PhD
Department of Medicine, McMaster University, Hamilton, Ontario, Canada

Seema Mital MD, FACC, FAHA, FRCP(C)
Professor of Paediatrics, University of Toronto and Head of Cardiovascular Research and Staff
Heart Function and Transplant Cardiologist, The Hospital for Sick Children, Toronto

Ioannis Ragoussis PhD
McGill University and Genome Quebec Innovation Centre, Montreal, Quebec, Canada

Chee L. Saw, PhD, HCLD
HLA Laboratory, Hematology Division, McGill University Health Centre, Montreal, Canada

About Us	For Researchers	For Patients
We are using genetic data to help minimize transplant rejection and complications of rejection.	Three distinct phases will integrate deeply-characterized transplant and DNA data.	Resources for transplant patients, including videos, recommendations, FAQs, and more.